Hypomagnesemia in hemodialysis patients: role of proton pump inhibitors. - Wikidata - awgldk - TriplyDB

Hypomagnesemia in hemodialysis patients: role of proton pump inhibitors.

Hypomagnesemia in hemodialysis patients: role of proton pump inhibitors.

http://www.wikidata.org/entity/Q38191806

about

The association between the use of proton pump inhibitors and the risk of hypomagnesemia: a systematic review and meta-analysis Hypomagnesemia Induced by Long-Term Treatment with Proton-Pump Inhibitors.The relationship between proton pump inhibitor use and serum magnesium concentration among hemodialysis patients: a cross-sectional study.Proton Pump Inhibitor Use and Magnesium Concentrations in Hemodialysis Patients: A Cross-Sectional Study Proton pump inhibitors use in hemodialysis patients and serum magnesium levels Sevelamer carbonate reduces the risk of hypomagnesemia in hemodialysis-requiring end-stage renal disease patients Magnesium Deficiency and Proton-Pump Inhibitor Use: A Clinical Review.Dialysate Composition for Hemodialysis: Changes and Changing Risk.Clinical aspects of magnesium physiology in patients on dialysis.Hypomagnesemia as a predictor of mortality in hemodialysis patients and the role of proton pump inhibitors: A cross-sectional, 1-year, retrospective cohort study.Proton Pump Inhibitor Usage and the Risk of Mortality in Hemodialysis Patients.Prevalence and outcomes of proton pump inhibitor associated hypomagnesemia in chronic kidney disease.

P2860

Q21090577-D1F4FE28-087A-42C2-846A-2D4D922E243D Q35614268-1B6C2354-A9A1-4E36-8769-4EE76C7017C8 Q35744487-DEFBF7F3-556E-4F86-8007-A0781D939835 Q35855528-9913D3BE-E7CE-47A0-84E0-9A8273266EA1 Q36493276-4F0F3538-F303-4CC6-AF4B-44077CF2B3C9 Q36951232-3924AAFF-E09E-4D19-B017-35262D02BFC5 Q38638067-EF258F75-EE51-4851-AFC4-B22A099BF6E9 Q39032556-D2E61588-14E5-45DD-BDF5-A518DEB71A96 Q39369171-677CC08C-3A16-47D5-A846-D16BED0FC448 Q40688800-D9A555E6-8AFE-4F7D-8629-6B9B524A1220 Q54974811-42C16FC4-0AC5-4957-8838-FA8CFCF88634 Q55385149-08B65E77-BD96-4EF1-B74D-02957EF4F097

P2860

Hypomagnesemia in hemodialysis patients: role of proton pump inhibitors.

http://www.wikidata.org/entity/Q38191806

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Hypomagnesemia in hemodialysis patients: role of proton pump inhibitors.

@en

type

label

Hypomagnesemia in hemodialysis patients: role of proton pump inhibitors.

@en

prefLabel

Hypomagnesemia in hemodialysis patients: role of proton pump inhibitors.

@en

P1433

Q38191806-41894BB8-4874-4474-A849-D7AFAAC3723C

P1476

Q38191806-601B30BD-AEF1-4B64-95A1-67E79F6A212D

P2093

Q38191806-0FC77691-6D95-42E9-8805-DF54DC7BDEBB

Q38191806-14ECE775-9616-4967-8D76-7E4F22A2521B

Q38191806-4A3D0D5E-ED2A-4690-B4FB-B22C355502AC

Q38191806-9A4AB3C5-7923-4112-9135-F43717FF6728

Q38191806-AC6FD171-F452-4303-996B-29B5FF59B0C1

Q38191806-F7D3DD85-1428-42B1-A1F9-DE0E39F5A201

P2860

Q38191806-1CF688DE-AA16-4AE4-9088-BB60EB4681CE

Q38191806-219BEB0F-F147-4CD6-ABEB-668CAC033212

Q38191806-22DD854F-03C1-4F70-9EF6-E9FAC6B3D5D3

Q38191806-22E37A5F-75E6-44F1-9E3B-CE9805F63684

Q38191806-2443422F-2FBF-43FD-8440-A1A340BD454F

Q38191806-2D0F374D-5C49-402E-85AC-0AD930122745

Q38191806-3CD6AECA-9DEC-4836-ABE4-7C1299645802

Q38191806-41C52E8F-7A00-4301-9AC6-13818235A494

Q38191806-432D9A23-D441-40AA-BCE9-1787D2A3275F

Q38191806-4B8E4C8D-6869-4CBD-91AF-BFAA5BBF728D

P304

Q38191806-A19E2309-E569-414E-BF34-56A64023F1C0

P31

Q38191806-C33C5B11-9F22-4270-B2F0-675F9EDBE407

P356

Q38191806-D0F3FB3C-6B10-46F1-9ADE-BF5CB173A828

P433

Q38191806-F66B4509-6DB0-474A-8E45-75C6DCED0FB3

P478

Q38191806-10609672-7596-425F-86B4-2CDB2390D764

P577

Q38191806-8227BCB6-0FEE-411F-A2CB-CB6D903726CE

P5875

Q38191806-C671D780-56E3-4371-B8B5-D67B058F944F

P698

Q38191806-945E166A-E862-4AE7-8CD5-D86491F25500

P356

P1433

American Journal of Nephrology

P1476

Hypomagnesemia in hemodialysis patients: role of proton pump inhibitors.

@en

P2093

Annming Hsieh

http://www.w3.org/2001/XMLSchema#string

David J Leehey

http://www.w3.org/2001/XMLSchema#string

James S Walter

http://www.w3.org/2001/XMLSchema#string

Mohamad Alhosaini

http://www.w3.org/2001/XMLSchema#string

Robert S Dieter

http://www.w3.org/2001/XMLSchema#string

Sanjay Singh

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability

The role of serum magnesium and calcium on the association between adiponectin levels and all-cause mortality in end-stage renal disease patients.

Magnesium carbonate is an effective phosphate binder for chronic hemodialysis patients: a pilot study.

Relationship between the serum parathyroid hormone and magnesium levels in continuous ambulatory peritoneal dialysis (CAPD) patients using low-magnesium peritoneal dialysate

Magnesium carbonate for phosphate control in patients on hemodialysis. A randomized controlled trial.

The role of magnesium binders in chronic kidney disease.

Hypomagnesemia in patients with type 2 diabetes.

Effect of magnesium on nerve conduction velocity during regular dialysis treatment.

Modeling and simulation of the effect of proton pump inhibitors on magnesium homeostasis. 1. Oral absorption of magnesium.

Relationship between serum magnesium levels and cardiovascular events in chronic kidney disease patients.

P304

204-209

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1159/000360011

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

39

http://www.w3.org/2001/XMLSchema#string

P577

2014-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260430609

http://www.w3.org/2001/XMLSchema#string

P698

24577494

http://www.w3.org/2001/XMLSchema#string